92 related articles for article (PubMed ID: 1343147)
21. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ
Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437
[TBL] [Abstract][Full Text] [Related]
22. Arterial carboxyhemoglobin concentrations in elderly patients with operable non-small cell lung cancer.
Yasuda H; Yamaya M; Ebihara S; Sasaki T; Inoue D; Kubo H; Sasaki H; Suzuki S
J Am Geriatr Soc; 2004 Sep; 52(9):1592-3. PubMed ID: 15341582
[No Abstract] [Full Text] [Related]
23. [The quantitative evaluation of the serum acute phase proteins (APP) of patients undergoing a curative resection for non-small cell lung cancer (NSCLC)].
Kasprzyk M; Dyszkiewicz W; Zwaruń D; Szydlik S; Leśniewska K; Krzyzanowski M
Przegl Lek; 2006; 63(10):936-40. PubMed ID: 17288188
[TBL] [Abstract][Full Text] [Related]
24. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
Ylisirniö S; Höyhtyä M; Mäkitaro R; Pääakkö P; Risteli J; Kinnula VL; Turpeenniemi-Hujanen T; Jukkola A
Clin Cancer Res; 2001 Jun; 7(6):1633-7. PubMed ID: 11410500
[TBL] [Abstract][Full Text] [Related]
25. [Possible causes for an increased content of blood peptide hormones in small-cell lung cancer].
Raĭkhlin NT; Smirnova EA; Blinova SA; Deĭneko GM; Bassalyk LS
Vopr Onkol; 1989; 35(2):203-7. PubMed ID: 2564709
[TBL] [Abstract][Full Text] [Related]
26. Association of serum reactive oxygen metabolite levels with different histopathological types of lung cancer.
Gencer M; Ceylan E; Aksoy N; Uzun K
Respiration; 2006; 73(4):520-4. PubMed ID: 16432293
[TBL] [Abstract][Full Text] [Related]
27. Significance of serum sialoglycoproteins in patients with lung cancer.
Patel PS; Baxi BR; Balar DB
Neoplasma; 1989; 36(1):53-9. PubMed ID: 2539569
[TBL] [Abstract][Full Text] [Related]
28. Pro-gastrin-releasing peptide (Pro-GRP), a tumor marker for small cell lung cancer.
Oremek GM; Sapoutzis N
Anticancer Res; 2003; 23(2A):895-8. PubMed ID: 12820319
[TBL] [Abstract][Full Text] [Related]
29. Serum and tissue distribution of a fragment of cytokeratin 19 (cyfra 21-1) in lung cancer patients.
Quillien V; Ramee MP; Bansard JY; Meritte H; Briens E; Logeais Y; Langanay T; Corbineau H; Dazord L
Anticancer Res; 1995; 15(6B):2857-63. PubMed ID: 8669879
[TBL] [Abstract][Full Text] [Related]
30. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer.
Milman N; Pedersen LM
Oncol Rep; 2002; 9(1):193-8. PubMed ID: 11748482
[TBL] [Abstract][Full Text] [Related]
31. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
32. [Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases].
Oremek GM; Seiffert UB; Siekmeier R; Kirsten R
Med Klin (Munich); 1995 Jan; 90(1):23-6. PubMed ID: 7533887
[TBL] [Abstract][Full Text] [Related]
33. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
[TBL] [Abstract][Full Text] [Related]
34. Comparative studies of CAM 123-6 and carcinoembryonic antigen for the serological detection of pulmonary adenocarcinoma.
Kohno N; Hirasawa Y; Kondo K; Fujioka S; Fujino S; Abe M; Yokoyama A; Hiwada K; Watanabe K; Nishimura J
Cancer Detect Prev; 1997; 21(2):124-8. PubMed ID: 9101072
[TBL] [Abstract][Full Text] [Related]
35. [Comparative study of serum lipid-bound sialic acid and carcinoembryonic antigen in patients with lung cancer].
Zhu X
Zhonghua Jie He He Hu Xi Za Zhi; 1990 Feb; 13(1):25-7, 61. PubMed ID: 2165867
[TBL] [Abstract][Full Text] [Related]
36. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.
Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V
Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651
[TBL] [Abstract][Full Text] [Related]
38. [Carcinoembryonic antigen and hormonal polypeptides in patients with lung cancer].
Afrikian MN; Zaĭtseva TI; Bogdasarov IuB
Med Radiol (Mosk); 1985 Apr; 30(4):7-10. PubMed ID: 2985906
[TBL] [Abstract][Full Text] [Related]
39. [Tissue polypeptide antigen in serum and tissue in patients with lung cancer].
Haga E
Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Apr; 28(4):595-604. PubMed ID: 2170727
[TBL] [Abstract][Full Text] [Related]
40. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
